These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 36123934

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R, Wijatyk A.
    Orphanet J Rare Dis; 2014 Nov 26; 9():169. PubMed ID: 25425121
    [Abstract] [Full Text] [Related]

  • 5. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
    Nowak A, Dormond O, Monzambani V, Huynh-Do U, Barbey F.
    Mol Genet Metab; 2022 Nov 26; 137(1-2):173-178. PubMed ID: 36087505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.
    J Am Soc Nephrol; 2018 Dec 26; 29(12):2879-2889. PubMed ID: 30385651
    [Abstract] [Full Text] [Related]

  • 11. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
    Deng M, Zhou H, He S, Qiu H, Wang Y, Zhao AY, Mu Y, Li F, Zhao AZ.
    Orphanet J Rare Dis; 2023 Sep 05; 18(1):275. PubMed ID: 37670350
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M, Brand E.
    Drugs; 2021 Nov 05; 81(17):1969-1981. PubMed ID: 34748189
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort.
    Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, Lavoie P, Abaoui M, Boutin M, Auray-Blais C.
    J Med Genet; 2021 Oct 05; 58(10):692-700. PubMed ID: 32963035
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):335-54. PubMed ID: 22946754
    [Abstract] [Full Text] [Related]

  • 19. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H.
    Mol Genet Metab; 2010 Jul 01; 100(3):257-61. PubMed ID: 20409739
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.